Upcoming Events
  1. TACT Board Teleconference (closed)

    August 28 - August 29
  2. ESMO 2017 Congress, Madrid Spain

    September 8 - September 12
  3. ***UPDATED*** 3rd ALTG Preceptorship in Lung Cancer, Melbourne VIC

    September 22 @ 12:00 pm - September 23 @ 5:00 pm UTC+10
  4. TACT General Assembly (closed), Yokohama Japan

    October 15
  5. 18th WCLC, Yokohama Japan

    October 15 - October 18

ALTG 15/001 SABR-OS: A randomised phase II trial to test the feasibility of randomising patients with peripheral stage I non-small cell lung cancer to either Stereotactic Ablative Radiotherapy (SABR) Or Surgery – F Hegi-Johnson

This trial was initially submitted as an international collaborative group phase II study titled SABRTOOTH however during 2014 it was recognised that, due to differences in the timing of funding and governance between the UK and Australia, a standalone Australian protocol would need to be developed. As a result, the SABR-OS phase II study was approved for development by the TROG Scientific committee in February 2015 (with ALTG collaboration). It is anticipated that the SABRTOOTH and SABR-OS trials will proceed to a joint international phase III trial.

This trial aims to assess the feasibility of recruiting patients, with histologically confirmed peripheral stage I NSCLC who are at higher risk of mortality and morbidity after surgery, into trial that randomises between multi-fraction Stereotactic Ablative Body Radiotherapy (SABR) and surgery (lobectomy or sub-lobar resection). Disease free and overall survival, toxicity and selected patient-reported outcomes will be assessed as secondary endpoints. A sub study looking at economic evaluation and a study of patient preferences using Discrete Choice Experiment (DCE) will also be included in the protocol.  A consumer meeting regarding the design and implementation of the consumer survey has been held. The DCE survey is being prepared and will be rolled out soon.

This study aims to recruit 72 participants over 3 years and the protocol is under development.

Study contacts

Trial Chair: Dr Fiona Hegi-Johnson     fionahegi@gmail.com)
Trial Co-ordinator: Angie Chung, TROG Cancer Research     SABR-OS@trog.com.au